

# Zolinza

---

**Generic Name:** vorinostat

**Drug Class:** [Chemotherapy Medications](#)

**Company:** Merck

**Approval Status:** Approved

**Generic Version Available:** No

---

## Drug Indication

Zolinza is an HDAC inhibitor approved for people with cutaneous T-cell lymphoma that does not respond to other systemic therapy.

---

## General Info



Zolinza is a histone deacetylase (HDAC) inhibitor that disables an enzyme that keeps DNA tightly coiled. It works by activating genes that halt cancer cell growth.

---

# Dosage

## Dosing Info:

Zolinza is a capsule taken once daily with food.

---

## Side Effects

Common side effects include diarrhea, fatigue, nausea and loss of appetite. Zolinza can cause depletion of red blood cells (anemia) and platelets (thrombocytopenia), which can lead to easy bleeding. Potential severe side effects include blood clots, gastrointestinal damage and high blood glucose. Zolinza may cause fetal harm if used during pregnancy.

---

For More Info: [https://www.merck.com/product/usa/pi\\_circulars/z/zolinza/zolinza\\_pi.pdf](https://www.merck.com/product/usa/pi_circulars/z/zolinza/zolinza_pi.pdf)

Patient Assistance Program Info: <http://www.merckhelps.com/ZOLINZA>

Last Reviewed: November 29, 2018

---

© 2026 Smart + Strong All Rights Reserved.

<http://beta.docker.cancerhealth.com/drug/zolinza-vorinostat>